The RIQAS Immunoassay EQA programme is designed to monitor the performance of up to 51 immunoassay parameters including therapeutic drugs; hormones and tumour markers. Four flexible and cost effective programme options are available.
Lyophilised material for enhanced stability

Submit results and view reports online via RIQAS.Net
World's largest EQA scheme ensuring peer groups are maximised
Flexible options available with bi-weekly or monthly reporting
Cycle Starts - RQ9125 (Bi-Weekly) – January/July 2026
RQ9130 (Monthly) – January 2026
Accredited to ISO/IEC 17043:2023
To find out more about RIQAS EQA or to get in touch with your local Randox Representative, enquire now.
| Description | Frequency | Size | Cat No | |
|---|---|---|---|---|
| Immunoassay 4 Parameters only + 4 pilots | Bi-weekly | 12 x 5ml | RQ9125/a | |
| Immunoassay 13 Parameters only + 4 pilots | Bi-weekly | 24 x 5 ml | RQ9125/b | |
| Immunoassay Full 50 Parameters + 4 pilots | Bi-weekly | 12 x 5 ml | RQ9125/c | |
| Immunoassay Full 51 Parameters + 4 pilots | Monthly | 12 x 5 ml | RQ9130 |
Immunoassay Speciality 1
Immunoassay Speciality 2
Anti-Müllerian Hormone (AMH)